Compare 10X Genomics Inc (TXG) vs Victoria's Secret & Co (VSXY) Price & Performance

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.

Victoria's Secret (VSXY) trades at $85.79, up 0.83% today, with a bullish technical trend and strong analyst support. Recent earnings beats and a 60% buy rating from analysts highlight improving fundamentals, while the stock shows robust profitability with a 45.27% ROE. The company's 2026 revenue guidance raise and global expansion efforts signal positive momentum, though valuation remains elevated with a P/E of 19.15.

The outlook for VSXY is positive, driven by earnings growth and brand revitalization, but risks include rich valuation and competitive pressures. Upside to the $86.80 consensus target appears achievable if execution continues, yet investors face margin volatility and macroeconomic sensitivity in the retail sector.